CFCI
PMCB icon

Comprehensive Financial Consultants Institutional’s PharmaCyte Biotech PMCB Stock Holding History

Comprehensive Financial Consultants Institutional’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14
Closed – – 398
2021
Q4 		$0 Buy
+14
New +$39 ﹤0.01% 504

Other funds holding PMCB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Comprehensive Financial Consultants Institutional's PMCB Position: Q1 2022 in Review

Comprehensive Financial Consultants Institutional sold out of PharmaCyte Biotech (PMCB) in Q1 2022, closing a stake of 14 shares.

Comprehensive Financial Consultants Institutional first reported a position in PMCB in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 25 funds tracked by Wall St. Rank hold PMCB as of Q1 2022.

  • Comprehensive Financial Consultants Institutional reported no remaining PharmaCyte Biotech position as of Q1 2022 after selling out during the quarter.
  • Comprehensive Financial Consultants Institutional sold 14 PharmaCyte Biotech shares in Q1 2022.
  • Comprehensive Financial Consultants Institutional first reported a position in PharmaCyte Biotech in Q4 2021 and held it in 1 quarter.
  • Comprehensive Financial Consultants Institutional's PharmaCyte Biotech position peaked at $0 in Q4 2021.
  • 25 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2022.

Based on Comprehensive Financial Consultants Institutional's 13F filing for Q1 2022, filed 11 May 2022.